GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenetp Inc (OTCPK:RGTPQ) » Definitions » Cash, Cash Equivalents, Marketable Securities

Regenetp (Regenetp) Cash, Cash Equivalents, Marketable Securities : $6.39 Mil (As of Mar. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Regenetp Cash, Cash Equivalents, Marketable Securities?

Regenetp's quarterly cash, cash equivalents, marketable securities declined from Sep. 2022 ($16.09 Mil) to Dec. 2022 ($11.45 Mil) but then stayed the same from Dec. 2022 ($11.45 Mil) to Mar. 2023 ($6.39 Mil).

Regenetp's annual cash, cash equivalents, marketable securities declined from Dec. 2020 ($25.52 Mil) to Dec. 2021 ($19.38 Mil) and declined from Dec. 2021 ($19.38 Mil) to Dec. 2022 ($11.45 Mil).


Regenetp Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Regenetp's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenetp Cash, Cash Equivalents, Marketable Securities Chart

Regenetp Annual Data
Trend Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Dec19 Dec20 Dec21 Dec22
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70.96 29.24 25.52 19.38 11.45

Regenetp Quarterly Data
Apr18 Jul18 Oct18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.72 20.52 16.09 11.45 6.39

Regenetp Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Regenetp  (OTCPK:RGTPQ) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Regenetp Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Regenetp's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Regenetp (Regenetp) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenetp Inc (OTCPK:RGTPQ) » Definitions » Cash, Cash Equivalents, Marketable Securities
Traded in Other Exchanges
N/A
Address
1960 South 4250 West, Salt Lake City, UT, USA, 84104
Regenetp Inc Formerly PolarityTE Inc is a clinical-stage biotechnology company developing regenerative tissue products and biomaterials. It's focused on transforming the lives of patients by discovering, designing, and developing regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences. Its product includes SkinTE used for repair, reconstruction, replacement, or regeneration of the skin in patients who have or require treatment of acute and chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts. It operates in two segments: the regenerative medicine business segment and the contract research segment.
Executives
Peter A Cohen director 40 WEST 57TH STREET, SUITE 2020, NEW YORK NY 10019
David B Seaburg director 1960 S 4250 W, SALT LAKE CITY UT 84104
Richard Hague officer: Chief Operating Officer 1960 S 4250 W, SALT LAKE CITY UT 84104
Cameron J. Hoyler other: General Counsel 1960 S 4250 W, SALT LAKE CITY UT 84104
Jeffrey Hansen Dyer director 4041-T HADLEY ROAD, SOUTH PLAINFIELD NJ 07080
Jessica Xiaolin Shen director POLARITYTE, INC. (NASDAQ: PTE), 1960 S. 4250 WEST, SALT LAKE CITY UT 84104
Chris Nolet director C/O REVANCE THERAPEUTICS, INC., 7555 GATEWAY BOULEVARD, NEWARK CA 94560
Paul Elliot Mann officer: Chief Financial Officer C/O ASP ISOTOPES INC., 433 PLAZA REAL, SUITE 275, BOCA RATON FL 33432
Jacob Alexander Patterson officer: Chief Financial Officer 14822 S. ROSESCAPE CIRCLE, HERRIMAN UT 84096
Denver Lough 10 percent owner, other: Prior D&O within 90 days 4041-T HADLEY ROAD, SOUTH PLAINFIELD NJ 07080
Rainer M Erdtmann director 1073 ARLINGTON BLVD., EL CERRITO CA 94530
Edward Winslow Swanson director, officer: Chief Operating Officer 181 DANTE AVE., TUCKAHOE NY 07070
Steve Gorlin director 150 GULF SHORE DRIVE, UNIT 601, DESTIN FL 32541
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Willie C Bogan director 1943, ROSECREST DRIVE, OAKLAND CA 94602